Document:

Exhibit 10.2

 

Spherix Incorporated

 

SPHERIX INCORPORATED

INCENTIVE COMPENSATION PLAN

 

1.             Purpose.  The purpose of this Incentive
Compensation Plan is to provide economic incentives to key personnel of Spherix
Incorporated and any subsidiary corporations to assist it in achieving its
business objectives.  This Incentive
Compensation Plan is designed to incentivize such key personnel to meet various
individual, division and corporate performance goals.

 

2.             Definitions.  For the purposes of the Plan,
the following terms shall have the following meanings:

 

“Annual Salary” – The annual base salary payable to
a Participant.

 

“Awards” - Incentive
compensation awards made pursuant to the Plan.

 

“Board” - The Board of
Directors of the Corporation (or any committee thereof as to which any duty or
function hereunder has been delegated by the Board of Directors).

 

“Calendar
Year” – January 1 – December 31 periods commencing January 1, 2005.

 

“CEO”
– The Chief Executive Officer of the Corporation.

 

“Corporation” – Spherix
Incorporated, a Delaware corporation.

 

“Participant” - Each of the
key employees of the Corporation and any Subsidiary selected to participate in
the Plan.  Unless otherwise determined by
the Board, the CEO, all Vice Presidents, all Division Directors and all Project
Managers shall be Participants.

 

“Performance Goals” – Target
objectives used for measurement of Awards under the Plan.  Performance Goals shall be either based on
total Corporation performance (“Corporate Performance Goals”), division performance
(“Division Performance Goals”), or individual performance (“Individual
Performance Goals”).

 

“Plan” - This Incentive
Compensation Plan, as set forth herein, or as
hereinafter amended.

 

“Subsidiary” – A corporation
at least fifty percent (50%) of the total combined voting power of all classes
of capital stock of which is owned by the Corporation, either directly or
through one or more of its Subsidiaries.

 

“Target Bonus” – An
aggregate dollar amount computed by multiplying a Participant’s Annual Salary by
45% for the CEO, 35% for each Vice President, 25% for each Division Director
and 20% for each Project Manager.

 

3.             Effective Date.  The
Plan will become effective for all Calendar Years commencing as of January 1,
2005, and shall continue until terminated by the Board.  The Board may terminate the Plan at any time
and for any reason.

 

1

 

4.             Regulations.  The Board shall have the power
to adopt rules and regulations (hereinafter referred to as the “Regulations”)
not inconsistent with the provisions of the Plan for the administration
thereof, and to alter, amend or revoke any Regulations so adopted.

 

5.             Interpretation and Administration of the Plan.  The
Board shall have full power and authority to interpret and administer the Plan
and the Regulations, and to make all decisions about the Plan and the
Regulations.  The decisions of the Board
with respect to any questions concerning the administration or interpretation
of the Plan or Regulations shall be final, conclusive, and binding.

 

6.             Establishment of Performance Goals.  Prior
to the commencement of each Calendar Year, the CEO shall submit to the Board
for review and approval a list of Participants together with Performance
Goals.  The Board shall review, make any
necessary changes and thereafter approve the Participants and related
Performance Goals for the upcoming Calendar Year.  Notwithstanding the foregoing, the
Participants and related Performance Goals for Calendar Year 2005 have been
approved by the Board as of the date of the adoption of this Plan.

 

7.             Performance Goals.  The
Performance Goals for each Participant shall be set forth in a writing signed
on behalf of the Corporation and distributed to each Participant.  Performance Goals established for the CEO
shall consist entirely of Corporate Performance Goals.  Performance Goals for the Vice Presidents may
consist of both Corporate Performance Goals and Division Performance Goals.  Performance Goals for Division Directors and
Project Managers may consist of Corporate Performance Goals, Division
Performance Goals and Individual Performance Goals.

 

8.             Weighting of Performance Goals. 
Performance Goals may be weighted by the Board in its discretion,
provided that in the event there is more than one Corporate Performance Goal or
Division Performance Goal for a Participant, each of the Performance Goals in
the relevant category shall be equally weighted (the “Weighted Percentage”).

 

9.             CEO Award.  If the CEO achieves all of the
CEO’s Performance Goals at the 100% level, the CEO shall be entitled to an
Award in an amount equal to the Target Bonus. 
In all other events, the Award shall be equal to the sum of the amounts
earned by the CEO for each of the Performance Goals based upon a sliding scale
of achievement of each such Performance Goal. 
In this event, the amount earned for each Performance Goal at the 100%
level shall first be calculated by dividing the Target Bonus by the number of
the CEO’s Performance Goals.  This
resulting amount shall then be multiplied by the percentage of actual
achievement of the Performance Goal provided that such percentage shall be zero
if the actual achievement is below 80% and the maximum percentage shall be 130%
even if the actual achievement is in excess of 130%.

 

10.           Vice President Awards.  If a
Vice President achieves all of the Vice President’s Performance Goals at the
100% level, the Vice President shall be entitled to an Award equal to the
Target Bonus.  In all other events, the
Award shall be in an amount equal to the sum of the amounts

 

2

 

earned by the Vice President for each of the
Performance Goals based upon a sliding scale of achievement.  In this event, the amount earned for each
Performance Goal at the 100% level shall first be calculated by multiplying the
Target Bonus by the Weighted Percentage. 
This resulting amount shall then be multiplied by the percentage of
actual achievement of the Performance Goal provided that such percentage shall
be zero if the actual achievement is below 80% and the maximum percentage shall
be 130% even if the actual achievement is in excess of 130%.

 

11.           Division Director Awards.  If a
Division Director achieves all of the Division Director’s Performance Goals at
the 100% level, the Division Director shall be entitled to an Award equal to
the Target Bonus.  In all other events,
the Award shall be in an amount equal to the sum of the amounts earned by the
Division Director for each of the Performance Goals based upon a sliding scale
of achievement.  In this event, the
amount earned for each Performance Goal at the 100% level shall first be
calculated by multiplying the Target Bonus by the Weighted Percentage.  This resulting amount shall then be
multiplied by the percentage of actual achievement of the Performance Goal
provided that such percentage shall be zero if the actual achievement is below
80% and the maximum percentage shall be 130% even if the actual achievement is
in excess of 130%.

 

12.           Project Manager Awards.  If a
Project Manager achieves all of the Project Manager’s Performance Goals at the
100% level, the Project Manager shall be entitled to an Award equal to the
Target Bonus.  In all other events, the
Award shall be in an amount equal to the sum of the amounts earned by the Project
Manager for each of the Performance Goals based upon a sliding scale of
achievement.  In this event, the amount
earned for each Performance Goal at the 100% level shall first be calculated by
multiplying the Target Bonus by the Weighted Percentage.  This resulting amount shall then be
multiplied by the percentage of actual achievement of the Performance Goal
provided that such percentage shall be zero if the actual achievement is below
80% and the maximum percentage shall be 130% even if the actual achievement is
in excess of 130%.

 

13.           Example of Award Calculation.  The
following is an example illustrating the manner in which an Award will be
calculated in the event that a Participant does not achieve all of the
Performance Goals at the 100% level.  The
example is based on a hypothetical Project Manager.  If the Project Manager’s Annual Salary is
$50,000.00 and the Board has established two (2) Corporate Performance Goals
(each weighted at 10%), one (1) Division Performance Goal (weighted at 30%) and
two (2) Individual Performance Goals (one weighted at 30% and the other at
20%), and the Project Manager achieves these Performance Goals at 90%, 100%,
125%, 150%, and 75%, the Project Manager will be entitled to an Award of
$9,550, as follows:

 

	
  Award for Corporate Performance Goal #1

  	
   

  	
  $

  	
  900

  	
   

  
	
  Award for Corporate Performance Goal #2

  	
   

  	
  1,000

  	
   

  
	
  Award for Division Performance Goal

  	
   

  	
  3,750

  	
   

  
	
  Award for Individual Performance Goal #1

  	
   

  	
  3,900

  	
   

  
	
  Award for Individual Performance Goal #2

  	
   

  	
  0

  	
   

  

 

3

 

14.           Determination and Payment of Awards.  The
Board shall determine the amount of Awards payable to the Participants no later
than the date the Corporation publicly announces its earnings for the relevant
Calendar Year.  All Awards shall be paid
in full in cash within five (5) days of the date of such public announcement.

 

15.           Change in Status.  A
Participant shall be entitled to an Award earned for a Calendar Year if and
only if the Participant remains a full time employee as of the end of the
Calendar Year for which the Award was earned. 
If a Participant is a full time employee at Calendar Year end but is not
a full time employee at the time of Award payment, the Participant shall still
be entitled to an Award payment unless the Participant’s employment was
terminated for cause as determined by the Board.  In the event a Participant changes categories
of employment during any Calendar Year, a new set of Performance Goals may be
established for the new category/position and the Award shall be pro-rated
based on the relative periods of time spent in each category.  In the event a new
Participant joins the Corporation in mid-Calendar Year, his Award shall be
pro-rated based on his time of service.

 

16.           Miscellaneous.

 

16.1.        Nothing contained in the Plan shall give any
Participant the right to be retained in the service of the Corporation or
affect the right of the Corporation to terminate the employment of any
Participant.  The adoption of the Plan
shall not constitute a contract of employment between the Corporation and any
Participant.

 

16.2.        Except insofar as may otherwise be required
by law, no amount payable at any time under the Plan shall be subject in any
manner to alienation by anticipation, sale, transfer, assignment, bankruptcy,
pledge, attachment, charge, or encumbrance of any kind nor in any manner be
subject to the debts or liabilities of any person and any attempt to so
alienate or subject any such amount, whether presently or thereafter payable,
shall be void.  If any person shall
attempt to, or shall, alienate, sell, transfer, assign, pledge, attach, charge,
or otherwise encumber any amount payable under the Plan, or any part thereof,
or if by reason of such Participant’s bankruptcy or other event happening at
any such time such amount would be made subject to such person’s debts or
liabilities or would otherwise not be enjoyed by such person, then the Board,
if it so elects, may direct that such amount be withheld and that the same or
any part thereof be paid or applied to or for the benefit of such person, his
or her spouse, children or other dependents, or any of them, in such manner and
proportion as the Board may deem proper.

 

16.3.        A Participant’s interest in amounts payable
under the Plan shall at all times be reflected on the Corporation’s books and
records as unsecured, unfunded obligation of the

 

4

 

Corporation. 
Participants shall have no right, title, or interest whatsoever in or to
any investment which the Corporation may make to aid it in meeting its
obligations under the Plan.  Nothing
contained in the Plan, and no action taken pursuant to its provisions, shall
create or be construed to create a trust of any kind, or a fiduciary
relationship between the Corporation and any Participant or any other
person.  To the extent that any person
acquires a right to receive payments from the Corporation under this Plan, such
right shall be no greater than the right of an unsecured general creditor of
the Corporation.  All payments to be made
hereunder shall be paid from the general funds of the Corporation, and no
special or separate fund shall be established and no segregation of assets
shall be made to assure payment of such amounts.

 

16.4.        All expenses and costs of the operation of
the Plan shall be borne by the Corporation.

 

16.5.        All Awards under the Plan are subject to
withholding, where applicable, for Federal, state and local taxes.

 

16.6.        The Plan shall be governed by and construed
in accordance with the internal laws of the State of Maryland, without
reference to principles of conflict of laws.

 

5Exhibit 10.1

 

REGISTRATION RIGHTS AND STOCK RESTRICTION
AGREEMENT

 

This Registration Rights and Stock Restriction Agreement, dated as of
this 10th day of May, 2005 (this “Agreement”), by and among ABIOMED, Inc.,
a Delaware corporation (“ABIOMED”), the stockholders of Impella CardioSystems
AG, a company organized under the laws of Germany (the “Company”), listed on Schedule I
hereto (the “Stockholders”) and Accelerated Technologies, Inc., as
attorney-in-fact and agent for the Stockholders (the “Stockholders’
Representative”).

 

WHEREAS, pursuant to a Share Purchase Agreement dated as of April 26,
2005 by and among ABIOMED, the Stockholders’ Representative, the Company, and
the Stockholders (the “Purchase Agreement”), the parties thereto have agreed,
subject to the terms and conditions set forth therein, that ABIOMED shall
acquire all of the outstanding shares of capital stock of the Company (the “Share
Purchase”);

 

WHEREAS, pursuant to the Purchase Agreement the Stockholders will
receive shares of ABIOMED Stock (as defined below);

 

WHEREAS, the Stockholders desire to obtain, and in connection with and
pursuant to the Purchase Agreement, ABIOMED has agreed, to grant each of the
Stockholders, registration rights as provided herein; and

 

WHEREAS, the Stockholders have agreed to certain restrictions with
respect to the sale of the shares of ABIOMED Stock they receive in the Share
Purchase;

 

NOW, THEREFORE, in consideration of the premises and the mutual
covenants and agreements herein contained, the parties agree as follows:

 

1.             Definitions of Certain Terms.  As used herein, the following terms shall
have the following meanings:

 

(a)           ABIOMED Stock:  the common stock, $.01 par value, of ABIOMED.

 

(b)           Exchange Act:  the United States Securities Exchange Act of
1934, as amended, and the rules and regulations of the SEC issued
thereunder, as they may, from time to time, be in effect.

 

(c)           Family Member: (i) with respect
to any individual, such individual’s spouse, any ancestors, siblings or
descendants (whether natural or adopted), any trust all of the beneficial
interests of which are owned by any of such individuals or by any of such
individuals together with any organization described in Section 501(c)(3) of
the Internal Revenue Code of 1986, as amended, the estate of any such
individual, and any corporation, association, partnership or limited liability
company all of the equity interests of which are owned by those

 

1

 

above described individuals, trusts or
organizations and (ii) with respect to any trust, the owners of the
beneficial interests of such trust.

 

(d)           Holder:  any Stockholder holding Registrable Shares
and any other person or entity holding Registrable Shares to whom the
registration rights granted in this Agreement have been transferred pursuant to
Section 10 hereof.

 

(e)           Permitted Transferee: (i) with
respect to a partnership, its partners or former partners in accordance with
their partnership interests, (b) with respect to a corporation, its
stockholders in accordance with their interest in the corporation, (c) with
respect to a limited liability company, its members or former members in
accordance with their interest in the limited liability company, (d) with
respect to an individual party, any Family Member of such party, (e) an
entity that is controlled by, controls, or is under common control with a
transferor, or (f) a party to this Agreement.

 

(f)            Registrable Shares:  the shares of ABIOMED Stock issued to the
Stockholders pursuant to the Purchase Agreement, and any other securities
issued by ABIOMED as a dividend or other distribution with respect to, or in
exchange for or in replacement of, such shares; provided, however,
Registrable Shares shall not include shares of ABIOMED Stock that (a) have
been registered under the Securities Act and disposed of pursuant to any
registration statement used to effect such registration, (b) have
otherwise been sold in the public securities markets in the United States of
America, (c) have been registered under the Securities Act on Form S-8
or any similar or successor form, or (d) may be sold by any Holder
pursuant to Rule 144 under the Securities Act without holding period and
volume limitations.

 

(g)           SEC: the United States Securities and
Exchange Commission, or any governmental agency succeeding to its functions.

 

(h)           Securities Act:  the United States Securities Act of 1933, as
amended, and the rules and regulations of the SEC issued thereunder, as
they may, from time to time, be in effect.

 

Capitalized terms used, but not otherwise defined, in this Agreement
shall have the meanings given to them in the Purchase Agreement.

 

2.             Shelf
Registration.  ABIOMED agrees
that, as soon as reasonably practicable following the closing of the
transactions contemplated in the Transaction Documents, and in any event within
thirty (30) days thereafter, it shall cause to be filed a registration
statement (a “Shelf Registration”) on Form S-3 or any other
appropriate form under the Securities Act for an offering of any or all of the
Registrable Shares issued as part of and with respect to, in exchange for or in
replacement of the Closing Consideration to be made on a delayed or continuous
basis pursuant to Rule 415 thereunder or any similar rule that may be
adopted by the SEC and permitting sales in ordinary course brokerage or dealer
transactions not involving any underwritten public offering.  ABIOMED will, at least three (3) business
days prior to filing the Shelf Registration Statement, furnish to the
Stockholders’ Representative a copy of the Shelf Registration Statement as
proposed to be filed, and allow the Stockholders’ Representative to review and
comment on the Shelf Registration Statement in accordance with Section 4(i).

 

2

 

Subject to Sections 5, 6 and 7
hereof, ABIOMED shall use its best efforts (a) to cause the Shelf
Registration to be declared effective by the SEC as soon as practicable, and in
no event later than ninety (90) days following the filing of such Shelf
Registration and (b) to keep the Shelf Registration continuously effective
until the earlier of (i) two (2) years (the “Time Period”) from the
date the Shelf Registration first becomes effective and (ii) the first
date on which no Registrable Shares covered by the Shelf Registration shall
constitute Registrable Shares (such period during which the Shelf Registration
is effective is intended to be referred to herein as the “Registration Period”).  If and to the extent that ABIOMED chooses to
pay any Additional Consideration or Contingent Consideration in the form of
ABIOMED Stock (the “Additional Shares”), ABIOMED hereby agrees that, as soon as
reasonably practicable following the issuance of such Additional Shares, and in
any event within thirty (30) days thereafter, it shall cause to be filed a
registration statement on Form S-3 or any other appropriate form
under the Securities Act for an offering of any or all of such Additional
Shares so issued, to be made on a delayed or continuous basis pursuant to Rule 415
thereunder or any similar rule that may be adopted by the SEC and
permitting sales in ordinary course brokerage or dealer transactions not
involving any underwritten public offering (in each case, an “Additional Shares
Registration”).  With respect to any
Additional Shares Registration, the parties shall have the same rights and
obligations set forth in this Agreement with respect to the Shelf Registration,
provided that any applicable time periods that are based on the Closing Date
with respect to the Shelf Registration shall be based on the date such
Additional Shares are issued with respect to any Additional Shares
Registration, and any time periods based on the date the Shelf Registration is
filed or is declared effective shall be based on the date the Additional Shares
Registration is filed or is declared effective, as the case may be.  

 

3.             Corporation
Registration.  Subject to Section 5
hereof, if at any time after the date hereof until the date three years from
the Closing Date, ABIOMED proposes to register any of the ABIOMED Stock under
the Securities Act in connection with the public offering of such securities
for its own account or for the accounts of other stockholders, solely for cash
on a form that would also permit the registration of the Registrable Shares
(other than registrations on Form S-4 or S-8, or any successor
form thereto, or any other registration statement in connection with, or
arising out of, an acquisition, merger or private placement involving ABIOMED),
ABIOMED shall, each such time, on up to four such occasions, promptly give each
Holder written notice of such proposal. 
Upon the written request of any Holder given within ten (10) days
after the mailing of any such notice by ABIOMED, ABIOMED shall use its best
efforts to cause to be registered under the Securities Act all of the
Registrable Securities that each such Holder has requested be registered.  The foregoing notwithstanding, ABIOMED may,
in its discretion, withdraw any registration statement prepared in connection
with any registration referred to in this Section 3 prior to the
effectiveness thereof, provided, however, that in the event of such withdrawal,
such registration shall not be treated as a counted registration for purposes
of Section 3 hereof.

 

4.             Registration
Procedures.  After ABIOMED
commences the registration of the Registrable Shares pursuant to the Shelf
Registration or a registration statement in accordance with Section 3
hereof (subject to ABIOMED’s right to withdraw any such registration statement
in accordance with Section 3) ABIOMED shall as expeditiously as possible,
at its expense (provided, however,
that Sections (d), (f), (g) and (i) shall only apply to the Shelf
Registration):

 

3

 

(a)           furnish to the Stockholders’
Representative such number of copies of such registration statement, each
amendment and supplement thereto (in each case including all exhibits thereto),
the prospectus included in such registration statement (including any
preliminary prospectus) and such other documents as the Stockholders’
Representative may reasonably request, each in conformity with the requirements
of the Securities Act, in order to facilitate the disposition of the
Registrable Shares owned by the Holders;

 

(b)           use its commercially reasonable best
efforts to register or qualify such Registrable Shares under such other
securities or “blue sky” laws of such United States jurisdictions as the
Stockholders’ Representative reasonably requests in writing and to do any and
all other acts and things that may be reasonably necessary or advisable to
register or qualify for sale in such United States jurisdictions the
Registrable Shares owned by the Holders; provided, however, that
ABIOMED shall not be required (i) to qualify to do business in any
jurisdiction where it is not then so qualified or (ii) to consent to
general service of process in any jurisdiction where it is not then so subject
to service of process;

 

(c)           use its commercially reasonable best
efforts to cause all Registrable Shares covered by such registration statement
to be listed on each United States securities exchange or market, if any, on
which similar securities issued by ABIOMED are then listed, provided
that the applicable listing requirements are satisfied;

 

(d)           prepare and file with the SEC such
amendments and supplements to such registration statement and the prospectus
contained therein as may be necessary to keep such registration statement
effective during the Registration Period, and to comply with the provisions of the
Securities Act with respect to the disposition of all Registrable Shares until
such time as all Registrable Shares have been disposed of in accordance with
the intended methods of disposition by the Holder set forth in such
registration statement;

 

(e)           as promptly as practicable after
becoming aware of such event, notify in writing each Holder or the Stockholders’
Representative promptly upon the happening of any event as a result of which a
prospectus included in such registration statement, as then in effect, includes
an untrue statement of a material fact or omits to state any material fact
required to be stated therein or necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading, and
use its commercially reasonable best efforts to prepare and furnish to each
Holder as soon as possible, as many copies of a supplement to or an amendment
of such prospectus (or prepare and file appropriate reports under the Exchange
Act) as such Holder reasonably requests so that, as thereafter delivered to the
purchasers of such Registrable Shares, such prospectus shall not include an
untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading;

 

(f)            as soon as practicable prior to
filing any amendment or supplement to such registration statement, furnish to
the Stockholders’ Representative a copy of such amendment or supplement as
proposed to be filed;

 

4

 

(g)           if such registration statement is
subject to review by the SEC, promptly respond to all comments and diligently
pursue reasonable resolution of any comments to the reasonable satisfaction of
the SEC;

 

(h)           comply, and continue to comply during
the period that such registration statement is effective under the Securities
Act, in all material respects with the provisions of the Securities Act and the
Exchange Act and applicable rules and regulations of the SEC thereunder
with respect to the disposition of all securities covered by such registration
statement, and make available to its security holders, as soon as reasonably
practicable, an earnings statement covering the period of at least twelve (12)
months, but not more than eighteen (18) months, beginning with the first full
calendar month after such registration statement is effective, which earnings
statement shall satisfy the provisions of Section 11(a) of the
Securities Act.

 

(i)            permit the Holders of Registrable
Shares being included in such registration statement and their legal counsel,
at such Holders’ sole cost and expense, to review and have a reasonable
opportunity to comment on such registration statement and all amendments and
supplements thereto at least three (3) business days prior to their filing
with the SEC and shall not file the Shelf Registration or any amendment or
supplement thereto should the Stockholders’ Representative reasonably object;

 

(j)            provide a transfer agent and
registrar, which may be a single entity, for the Registrable Shares at all
times; and

 

(k)           upon evidence of compliance by the
Holders with all applicable securities laws, including, without limitation,
compliance with any prospectus delivery requirements, cooperate with the
Holders of Registrable Shares being offered pursuant to such registration
statement to issue and deliver certificates (not bearing any restrictive
legends, unless required by applicable securities laws or Section 11 of
this Agreement) representing Registrable Shares to be offered pursuant to such
registration statement within five trading days after delivery of certificates
to the Company’s transfer agent, with notice to the Company, and enable such
certificates to be in such denominations or amounts as the Holders may
reasonably request and registered in such names as the Holders may request.

 

5.             Underwriting
Requirements.

 

(a)           In connection with any offering
involving an underwriting of shares being issued by ABIOMED other than the
offering contemplated by Section 2 hereof, ABIOMED shall not be required
under Section 3 hereof to include any of the Holders’ Registrable Shares
in such underwriting unless such Holders accept the terms of the underwriting
as agreed upon between ABIOMED and the underwriters selected by it.  If the total amount of securities that all
Holders request to be included in an underwritten offering exceeds the amount
of securities that the underwriters reasonably believe compatible with the
success of the offering based on marketing factors, ABIOMED shall only be
required to include in the offering so many of the securities of the selling
Holders as the underwriters reasonably believe will not jeopardize the success
of the offering (the securities so included to be apportioned pro rata among
the selling Holders according to the total amount of securities owned by said
selling Holders or in such other proportions as shall mutually be agreed to by
such selling Holders).

 

5

 

(b)           In connection with registrations
under Section 2 hereof, ABIOMED shall have the right to designate the
managing underwriter or underwriters.

 

6.             Material,
Non-Public Information; Stop Order; Supplement to the Prospectus; ABIOMED’s
Insider Trading Policies.

 

(a)           Notwithstanding the foregoing, if
ABIOMED shall determine in good faith, after consultation with its counsel,
that it is in possession of material, non-public information, the disclosure of
which would not be in the best interest of ABIOMED, ABIOMED may, upon written
notice to the Stockholders’ Representative, delay the effectiveness of the
Shelf Registration or any other registration of Registrable Shares for a
reasonable period of time or suspend the effectiveness of the Shelf
Registration Statement or other registration statement; provided, that
ABIOMED may delay the effectiveness of such Shelf Registration Statement or
other registration statement for no more than five (5) business days after
such information becomes public or is no longer material; provided, further,
that ABIOMED shall limit its delay or suspension of the effectiveness of such
registration, in the aggregate to 90 trading days in any 12-month period.

 

(b)           ABIOMED will notify the Stockholders’
Representative as promptly as practicable of (i) the issuance of any stop
order suspending the effectiveness of the Shelf Registration or other
registration statement or (ii) the receipt by ABIOMED of any notification
with respect to the suspension of the qualification of the Registrable Shares
for sale in any jurisdiction.  Upon
receipt of any such notice, the Holders shall cease to offer and sell any
Registrable Shares pursuant to the Shelf Registration or other registration
statement in the jurisdiction to which such stop order or suspension
relates.  The Stockholders’
Representative and the Holders hereby agree that the existence and contents of
any such notice are strictly confidential and may not be disclosed to any third
party without ABIOMED’s express written consent.  ABIOMED shall use all reasonable efforts to
prevent the issuance of any such stop order or the suspension of any such
qualification and, if any such stop order is issued or any such qualification
is suspended, to obtain as soon as possible the withdrawal or revocation
thereof, and will notify the Stockholders’ Representative at the earliest
practicable date of the date on which the Holders may offer and sell
Registrable Shares pursuant to the Shelf Registration or other registration
statement.

 

(c)           ABIOMED will notify the Stockholders’
Representative as promptly as practicable of the occurrence of any event or the
existence of any state of facts that ABIOMED determines in good faith, after
consultation with its counsel, is material to ABIOMED, is non-public
information and should be set forth in the prospectus used in connection with
the Shelf Registration or other registration of Registrable Shares.  Immediately upon receipt of such notice, the
Holders shall cease to offer or sell any Registrable Shares pursuant to such
prospectus, cease to deliver or use such prospectus and, if so requested by
ABIOMED, return to ABIOMED, at its expense, all copies (other than permanent
file copies) of such prospectus.  The
Stockholders’ Representative and the Holders hereby agree that the existence
and contents of any such notice are strictly confidential and may not be
disclosed to any third party without ABIOMED’s express written consent.  ABIOMED will, as soon as the information
becomes available in a form such that it may be included in an amendment or
supplement to the prospectus, use all reasonable efforts to amend or supplement
such prospectus in order to set

 

6

 

forth or reflect such event or state of facts
as soon as possible; it  being  understood that in the event
that ABIOMED determines in good faith, after consultation with its counsel,
that the disclosure of such material non-public information would not be in the
best interest of ABIOMED, ABIOMED may delay the filing of such an amendment or
supplement to the prospectus for a period of time to extend no longer than
ninety (90) days from the occurrence of such event or existence of such state
of fact; provided, that ABIOMED may delay the filing of such amendment
or supplement for no more than five (5) business days after such
information becomes public or is no longer material.  ABIOMED will furnish copies of such amendment
or supplement to the prospectus to the Stockholders’ Representative.  In the event Holders are prevented from
selling Registrable Shares through the Shelf Registration as a result of this Section 6(c),
then the Time Period shall be extended by the number of days that such Holders
are prevented from making such sales as a result of this Section 6(c).

 

(d)           Each Holder agrees, if and for so
long as he or she is an employee of ABIOMED or any of ABIOMED’s subsidiaries,
to comply with the ABIOMED’s standard policy concerning the purchase and sale
of securities of ABIOMED applicable to similarly situated employees.

 

7.             Information Concerning the Sellers.

 

(a)           It shall be a condition precedent to
the obligations of ABIOMED to take any actions pursuant to Sections 2, 3, 4 and
6 hereof that each Holder (i) conform to all applicable requirements of the
Securities Act and the Exchange Act with respect to the offering and sale of
securities, (ii) advise each underwriter, broker or dealer through which
any of such Registrable Shares are offered that such Registrable Shares are
part of a distribution that is subject to the prospectus delivery requirements
of the Securities Act, (iii) furnish to ABIOMED in writing such
information regarding themselves, the Registrable Shares held by them and the
intended method of disposition of such shares as ABIOMED shall reasonably
request and as shall be required under applicable securities laws in connection
with the action to be taken by ABIOMED, including the preparation of (A) the
prospectus (or any amendment or supplement thereto) with respect to such
offering and (B) any qualification of such Registrable Shares under state
securities or “blue sky” laws, and (iv) promptly notify ABIOMED of the
occurrence, from the date on which such information or documents are furnished
to the date of the closing for the sale of such Registrable Shares, of any
event relating to such Holder that is required under the Securities Act to be
set forth in the prospectus (or any amendment or supplement thereto).

 

(b)           At the end of the Registration Period
the Holders shall discontinue sales of Registrable Shares pursuant to the Shelf
Registration after ABIOMED has given notice to the Stockholders’ Representative
of its intention to remove from registration the securities covered by the
Registration Statement which remain unsold, and the Stockholders’
Representative shall notify ABIOMED immediately upon receipt of such notice
from ABIOMED of the number of shares of the Holders that are registered but
remain unsold.

 

8.             Expenses
of Registration.  ABIOMED
shall pay all expenses incident to its performance of or compliance with this
Agreement and registration of Registrable Shares in connection herewith,
including (a) all SEC, stock exchange or market and National Association
of Securities Dealers, Inc. registration and filing fees, (b) all
fees and expenses incurred in

 

7

 

complying with securities or “blue
sky” laws, (c) all expenses incurred in connection with the preparation,
printing and distribution of the registration statement and prospectus and any
other supplement or amendment thereto and the mailing and delivery of copies
thereof to the Holders, including all printing, messenger and delivery expenses
and (d) all fees and disbursements of ABIOMED’s independent public
accountants and counsel (all of such expenses herein referred to as “Registration
Expenses”).  The Registration Expenses
shall not include any sales or underwriting discounts, commissions or fees
attributable to the sale of the Registrable Shares or the fees and expenses of
counsel to the Holders, which shall be borne by the Holders.

 

9.             Indemnification and Contribution.  

 

 (a)          In
the event that Registrable Shares are included in a registration statement
pursuant to the terms of this Agreement, ABIOMED agrees to indemnify and hold
harmless, to the extent permitted by law and subject to the terms of this
Agreement, each Holder, its directors, officers, partners, and each person, if
any, who controls such Holder (within the meaning of the Securities Act)
against any losses, claims, damages, liabilities and expenses (including
reasonable attorneys’ fees and disbursements), joint or several, arising out of
or based upon any untrue or alleged untrue statement of a material fact
contained in such registration statement (or any amendment thereto) or any
preliminary, final or supplemental prospectus contained therein (or any
amendment or supplement thereto) or any omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the
statements made therein in the light of the circumstances under which they were
made not misleading, and the Company shall reimburse the Holder, and each such
director, officer, partner, underwriter and controlling person for any legal or
any other expenses reasonably incurred by them in connection with
investigating, defending or settling any such loss, claim, damage, liability or
expense and any related action or proceeding; provided, however,
that ABIOMED shall not be liable to any Holder or any person who controls such
Holder (within the meaning of the Securities Act) to the extent that any such
loss, claim, damage, liability or expense arises out of, or is based upon any
such untrue or alleged untrue statement, or any such omission, if such
statement or omission shall have been made in reliance upon and in conformity
with information relating to such Holder or person furnished to ABIOMED in
writing by or on behalf of any such Holder or person for use in the preparation
of such registration statement (or any amendment thereto) or any prospectus
contained therein (or any amendment or supplement thereto).

 

(b)           In connection with any such
registration statement, each Holder agrees to indemnify, to the extent
permitted by law and subject to the terms of this Agreement, ABIOMED, its
directors, officers, employees and agents and each person who controls ABIOMED
(collectively, the “ABIOMED Group”) (within the meaning of the Securities Act)
against any losses, claims, damages, liabilities and expenses (including
reasonable attorneys’ fees and disbursements; collectively, all such amounts
are hereinafter referred to as “ABIOMED Claims”) arising out of or based upon
any untrue or alleged untrue statement of a material fact contained in any such
registration statement (or any amendment thereto) or any prospectus contained
therein (or any amendment or supplement thereto) or any omission or alleged
omission to state therein a material fact required to be stated therein or
necessary to make the statements made therein in the light of the circumstances
under which they were made not misleading, to the extent that such untrue
statement or omission was made in reliance upon and in conformity with
information furnished to ABIOMED in writing by or on behalf of such Holder for
use in the

 

8

 

preparation of such registration statement
(or any amendment thereto) or any prospectus contained therein (or any
amendment or supplement thereto).

 

(c)           Each party entitled to
indemnification under this Section 9 shall give notice to the party
required to provide indemnification promptly after such indemnified party has
actual knowledge of any claim as to which indemnity may be sought, and shall
permit the indemnifying party to assume the defense of any such claim or any
litigation resulting therefrom; provided that counsel for the
indemnifying party, who shall conduct the defense of such claim or litigation,
shall be approved by the indemnified party (whose approval shall not be
unreasonably withheld or delayed); and provided, further, that
the delay or failure of any indemnified party to give notice as provided herein
shall not relieve the indemnifying party of its obligations under this Section 9,
except to the extent that the indemnifying party is actually prejudicial by
such delay or failure.  The indemnified
party may participate in such defense at such party’s expense; provided,
however, that the indemnifying party shall pay such expense if the
indemnified party shall have reasonably concluded that there may be a conflict
between the positions of the indemnifying party and the indemnified party in
conducting the defense of any such claim or litigation resulting therefrom or
the indemnifying party fails to defend such claim in a reasonably diligent
manner.  No indemnified party shall
consent to entry of any judgment or settle any claim or litigation without the
prior written consent of the indemnifying party.

 

(d)           If the indemnification provided for
in this Section 9 from the indemnifying party is unavailable to an
indemnified party hereunder in respect of any losses, claims, damages,
liabilities or expenses referred to therein as a result of a binding judicial
determination that such indemnification may not be enforced in such case
notwithstanding this Agreement, the indemnifying party, in lieu of indemnifying
such indemnified party, shall contribute to the amount paid or payable by such
indemnified party as a result of such losses, claims, damages, liabilities or
expenses in such proportion as is appropriate to reflect the relative fault of
the indemnifying party and indemnified parties in connection with the actions
which resulted in such losses, claims, damages, liabilities or expense, as well
as any other relevant equitable considerations. 
The relative fault of such indemnifying party and indemnified parties
shall be determined by reference to, among other things, whether any action in
question, including any untrue or alleged untrue statement of material fact or
omission or alleged omission to state a material fact, has been made by, or
relates to information supplied by, such indemnifying party or indemnified
parties, and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such action. 
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation.

 

10.           Transfer
of Registration Rights.  The
registration rights of any Holder (and of any Permitted Transferee of any
Holder or its Permitted Transferees) under this Agreement with respect to any
Registrable Shares may be transferred to any Permitted Transferee as a gift,
partnership distribution or other non-sale related transfer without
consideration (a “Permitted Transfer”); provided that (a) ABIOMED is given
written notice by the Holder at the time of such Permitted Transfer stating the
name and address of the Permitted Transferee and identifying the Registrable Shares
with respect to which the rights under this Agreement are being assigned, (b) such
Permitted Transferee executes and delivers such agreements as ABIOMED may
reasonably require in order to confirm that such Permitted Transferee agrees to
be bound by this Agreement

 

9

 

and the Purchase Agreement, and
(c) notwithstanding anything to the contrary contained in this Agreement,
ABIOMED shall not be obligated to file any post-effective amendments or
prospectus supplements to any outstanding registration statements contemplated
by this Agreement for the purposes of updating the selling stockholders listed
in such registration statements to include the Permitted Transferees other than
on a quarterly basis in connection with the timing of its filing of annual
reports on Form 10-K and quarterly reports on Form 10-Q
and such Permitted Transferees shall not be allowed to sell any shares covered
by the Permitted Transfer under any such registration statement until such time
as such post-effective amendments or prospectus supplements are filed unless it
is determined, to the satisfaction of ABIOMED’s counsel, that no such
post-effective amendments or prospectus supplements are required under
applicable securities laws.

 

11.           Restrictions
on the Sale of Registrable Shares.  Each
Holder covenants and agrees that notwithstanding any other provision in this
Agreement:

 

(a)           such Holder shall not sell, transfer,
hedge, pledge, hypothecate, assign or otherwise convey any interest in
(collectively, “sell”) any Closing Consideration for a period of six (6) months
from the date of the Closing under the Purchase Agreement, at which point such
restrictions shall lapse as to fifty percent (50%) of such Holder’s Closing
Consideration;

 

(b)           the restrictions set forth in Section 11(a) shall
lapse as to one hundred percent (100%) of the Closing Consideration twelve (12)
months after the date of the Closing under the Purchase Agreement.

 

Notwithstanding the foregoing, such Holder shall not sell any
Registrable Shares unless they are registered under the Securities Act or
unless an exemption from the registration requirements thereof is
available.  Until the date such
Registrable Shares are eligible to be sold under this Section 11, in
addition to all other legends required by this Agreement or deemed appropriate
by ABIOMED, the certificates representing such shares shall bear a legend
substantially in the following form:

 

“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS
ON TRANSFER PURSUANT TO A REGISTRATION RIGHTS AND STOCK RESTRICTION AGREEMENT
DATED AS OF MAY 10, 2005, A COPY OF WHICH WILL BE FURNISHED TO THE HOLDER
HEREOF UPON REQUEST.”

 

12.           Investment
Representations. 

 

(a)           Each Stockholder represents and
warrants to ABIOMED as follows:

 

(i)            Such Stockholder understands that
the shares of ABIOMED Stock to be received by such Stockholder pursuant to the
Purchase Agreement will not have been registered or qualified under the
Securities Act or under the securities laws of any jurisdiction, and other than
pursuant to its obligations under this Agreement, ABIOMED is not, nor will it
be, under any obligation to register such shares of ABIOMED Stock under the
Securities Act or the Securities laws of any jurisdiction.  Such Stockholder further understands that
such shares of

 

10

 

ABIOMED Stock will constitute “restricted
securities” within the meaning of Rule 144 promulgated under the
Securities Act and that, as such, such shares of ABIOMED Stock must be held
indefinitely unless they are subsequently registered under the Securities Act
or unless an exemption from the registration requirements thereof is available.

 

(ii)           Such Stockholder is acquiring the
shares of ABIOMED Stock to be received by it pursuant to the Purchase Agreement
for its own account for investment and not for, with a view to or in connection
with any resale or distribution thereof in a manner that violates the
Securities Act or any other applicable securities laws.

 

(iii)          Such Stockholder by reason of its
business and financial experience, and the business and financial experience of
those persons retained by such Stockholder to advise it with respect to its
investment in the shares of ABIOMED Stock to be received by it hereunder, has
such knowledge, sophistication and experience in business and financial matters
as to be capable of evaluating the merits and risks of the prospective
investment, and is able to bear the economic risk of such investment and is
able to afford a complete loss of such investment.  Such Stockholder acknowledges and understands
that ABIOMED’s filings with the SEC are publicly available for review via the
SEC’s EDGAR website.  Such Stockholder is
an “accredited investor” within the meaning of Rule 501 promulgated under
the Securities Act.

 

(b)           Except as set forth in Schedule I,
each Stockholder whose address listed on Schedule I is located
outside the United States further represents and warrants to ABIOMED as
follows:

 

(i)            If such Stockholder is an
individual, the address for such Stockholder set forth on Schedule I
is the true jurisdiction of citizenship, residence and domicile of such
Stockholder, and such Stockholder has no present intention of becoming a
citizen, resident or domiciliary of any other state or jurisdiction.  If a corporation, trust, partnership or other
entity, such Stockholder was organized under the laws of the jurisdiction of
its principal place of business and has its principal place of business at the
address set forth for such Stockholder on Schedule I.

 

(ii)           Such Stockholder, if an individual,
was present in the United States during the current year and the two preceding
calendar years for less than 183 days in each year.

 

(iii)          No offer of the ABIOMED Stock was made
to such Stockholder in the United States.

 

(iv)          At the time such Stockholder executed
this Agreement, such Stockholder was located outside the United States.

 

(v)           Such Stockholder is not a U.S. Person
and is not acquiring ABIOMED Stock hereunder for the account or benefit of any
U.S. Person.

 

(vi)          Such Stockholder agrees to resell the
ABIOMED Stock to be acquired hereunder only in accordance with the provisions
of Regulation S of the Securities Act,

 

11

 

pursuant to registration under the Securities
Act, or pursuant to an available exemption from registration under the
Securities Act.  The undersigned also
agrees not to engage in hedging transactions with regard to such ABIOMED Stock.

 

13.           Stockholders’
Representative.

 

(a)           In order to administer efficiently
the registration of the Registrable Shares and the defense and/or settlement of
any ABIOMED Claims for which the Holders may be required to indemnify the
ABIOMED Group pursuant to Section 9 hereof, the Holders hereby designate
the Stockholders’ Representative as their representative and agent under this
Agreement, and the Stockholders’ Representative hereby accepts such
appointment.

 

(b)           The Holders hereby authorize and
appoint the Stockholders’ Representative to be their exclusive representative
and attorney in fact with respect to all matters arising out of this Agreement
and the Holders shall not make any independent agreement or arrangement with
ABIOMED with respect to any such matter. 
In furtherance of the foregoing, the Stockholders’ Representative shall
be authorized, on behalf of the Holder, to (i) take any action permitted
or required to be taken by any Holder pursuant to this Agreement; (ii) take
all action necessary in connection with the defense and/or settlement of any
ABIOMED Claims for which the Holders may be required to indemnify members of
the ABIOMED Group pursuant to Section 9 hereof, (iii) give and
receive all notices required to be given under this Agreement, and (iv) take
any and all additional action as is contemplated to be taken by or on behalf of
the Holders by the terms of this Agreement.

 

(c)           In the event that the Stockholders’
Representative dies, becomes unable to perform his or its responsibilities
hereunder or resigns or is removed from such position (in accordance with the
provisions of Section 2.8(c) of the Purchase Agreement), a successor
Stockholders’ Representative shall be appointed pursuant to the terms of Section 2.8(c) of
the Purchase Agreement.

 

(d)           All decisions and actions by the
Stockholders’ Representative, including actions under this Agreement and the
defense or settlement of any ABIOMED Claims for which the Holders may be
required to indemnify members of the ABIOMED Group pursuant to Section 9
hereof, shall be binding upon all of the Holders, and no Holder shall have the
right to object, dissent, protest or otherwise contest the same.

 

(e)           By their adoption of this Agreement,
the Holders agree that:

 

(i)            ABIOMED shall be able to rely
conclusively on the instructions and decisions of the Holders’ Representative
relating to the Shelf Registration or any other registration of Registrable
Shares or to the settlement of any ABIOMED Claims for indemnification by
members of the ABIOMED Group pursuant to Section 9 hereof or any other
actions permitted or required to be taken by the Stockholders’ Representative
hereunder, and no Person shall have any cause of action against any member of
the ABIOMED Group for any action taken by any member of the ABIOMED Group in
reliance upon the instructions or decisions of the Stockholders’
Representative;

 

12

 

(ii)           all actions, decisions and
instructions of the Stockholders’ Representative shall be conclusive and
binding upon all of the Holders and no Holder shall have any cause of action
against the Stockholders’ Representative for any action taken or not taken,
decision made or instruction given by the Stockholders’ Representative arising
out of or in connection with the acceptance or administration of his or its
duties hereunder, except for fraud or willful breach of this Agreement by the
Stockholders’ Representative;

 

(iii)          the provisions of this Section 13
are independent and severable, are irrevocable and coupled with an interest and
shall be enforceable notwithstanding any rights or remedies that any Holder may
have in connection with the transactions contemplated by this Agreement; and

 

(iv)          the provisions of this Section 13
shall be binding upon the executors, heirs, legal representatives, successors
and assigns of each Holder, and any references in this Agreement to a Holder or
the Holders shall mean and include the successors to the Stockholders’ rights
hereunder, whether pursuant to testamentary disposition, the laws of descent
and distribution or otherwise.

 

(f)            Each Holder consents to the
appointment of the Stockholders’ Representative pursuant to Section 2.8 of
the Purchase Agreement and agrees to be bound by the provisions of Section 2.8
of the Purchase Agreement (the provisions of which are hereby incorporated by
reference mutatis  mutandis).

 

(g)           ABIOMED shall have no liability for
any fees or expenses of the Stockholder Representative under this Agreement.

 

14.           Compliance
with Rule 144.  ABIOMED
agrees to (i) satisfy the conditions of Rule 144(c) under the
Securities Act with respect to current public information about ABIOMED; and (ii) use
its best efforts to file with the SEC in a timely manner all reports and other
documents required to be filed by ABIOMED under the Exchange Act, provided,
however, that ABIOMED’s obligations under this Section shall terminate
upon the earlier of (a) four years following the Closing Date, (b) the
date the Impella Stockholders no longer hold shares of ABIOMED Stock issued to
them pursuant to the Purchase Agreement, and (c) such time as ABIOMED no
longer has a class of shares registered under the Exchange Act.

 

15.           Amendments
and Supplements.  This
Agreement may not be amended, modified or supplemented by the parties hereto in
any manner, except by an instrument in writing signed by ABIOMED and the
Stockholders’ Representative.

 

16.           No
Waiver.  The terms and
conditions of this Agreement may be waived only by a written instrument signed
by (a) the Stockholders’ Representative in the case where a Stockholder or
the Stockholders’ Representative is waiving compliance and (b) by ABIOMED
in the case where ABIOMED is waiving compliance.  The failure of any party hereto to enforce at
any time any of the provisions of this Agreement shall in no way be construed
to be a waiver of any such provision, nor in any way to affect the validity of
this Agreement or any part hereof or the right of such party thereafter to
enforce each and every such provision. 
No waiver of any breach of or non-compliance with this Agreement shall
be held to be a waiver of any other or

 

13

 

subsequent breach or
non-compliance.  The rights and remedies
herein provided are cumulative and are not exclusive of any rights or remedies
that any party may otherwise have at law or in equity.

 

17.           Governing
Law.  This Agreement shall be
governed by, and construed and enforced in accordance with, the substantive
laws of the State of Delaware, without regard to its principles of conflicts of
laws.

 

18.           Notice.  All notices and other communications
hereunder shall be in writing and shall be deemed given if delivered by hand,
sent by facsimile transmission with confirmation of receipt, or sent via a
reputable overnight courier service with confirmation of receipt requested to
the parties at the following addresses (or at such other address for a party as
shall be specified by like notice), and shall be deemed given on the date on
which delivered by hand or otherwise on the date of receipt as confirmed:

 

To ABIOMED:

 

ABIOMED, Inc.

22 Cherry Hill Drive

Danvers, MA 01923

USA

Attention:  President

Facsimile: 
(01) 978-777-8411

 

With a copy to:

Foley Hoag LLP

155 Seaport Boulevard

Boston, Massachusetts 02210

USA

Attention:  Peter M. Rosenblum, Esq.

Facsimile:  (01) 617 832-7000

 

To any Holder:

 

c/o Accelerated Technologies, Inc., as
Stockholders’ Representative

401 Hackensack Avenue

Hackensack, NJ  07601

USA

Attention:      Richard Geoffrion

Facsimile:       (201) 487-2005

 

With a copy to:

 

Fulbright & Jaworski, L.L.P.

666 Fifth Avenue

New York, New York 10103

 

14

 

Attn: Joseph F. Daniels, Esq.

Facsimile: (212) 318-3400

 

19.           Construction
of Agreement.  A reference to
a Section shall mean a Section in this Agreement unless otherwise expressly
stated.  The titles and headings herein
are for reference purposes only and shall not in any manner limit the
construction of this Agreement which shall be considered as a whole.  The words “include,” “includes” and “including”
when used herein shall be deemed in each case to be followed by the words “without
limitation.”

 

20.           Entire
Agreement, Assignability, etc.. 
This Agreement and the Purchase Agreement and the documents and other
agreements among the parties hereto and thereto as contemplated by or referred
to herein or therein constitute the entire agreement among the parties with
respect to the subject matter hereof and supersede all other prior agreements
and understandings, both written and oral, between the parties with respect to
the subject matter hereof.  This
Agreement shall be binding upon and inure to the benefit of the parties hereto
and their respective successors and permitted assigns.  This Agreement is not intended to confer upon
any person other than the parties hereto any rights or remedies hereunder,
except as otherwise expressly provided herein and shall not be assignable by
the Stockholders by operation of law or otherwise, except as provided in Section 10
hereof.

 

21.           Validity.  The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability of
any other provision of this Agreement, each of which shall remain in full force
and effect.

 

22.           Counterparts.  This Agreement may be executed in one or more
counterparts, all of which together shall constitute one and the same
Agreement.

 

*    *   
*    *    *

 

15

 

IN WITNESS WHEREOF, the parties have caused
this Registration Rights and Stock Restriction Agreement to be executed as an agreement
under seal as of the date first written above.

 

	
   

  	
  ABIOMED, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  /s/ Javier
  Jimenez

  
	
   

  	
  Name: Javier
  Jimenez

  
	
   

  	
  Title: VP
  Operations

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  STOCKHOLDERS’ REPRESENTATIVE

  
	
   

  	
   

  
	
   

  	
  ACCELERATED TECHNOLOGIES, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  /s/ John P.
  Brancaccio

  
	
   

  	
  Name: John
  P. Brancaccio

  
	
   

  	
  Title: CFO

  

 

[Signature Page to Registration Rights Agreement]

 

 

	
   

  	
  STOCKHOLDERS

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  ACCELERATED
  TECHNOLOGIES, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ John P.
  Brancaccio

  
	
   

  	
   

  	
   

  	
  Name: John
  P. Brancaccio

  
	
   

  	
   

  	
   

  	
  Title: CFO

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  MRNA FUND II
  L.P.

  
	
   

  	
   

  	
  By: OBP
  Management IV L.P., its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Jeffrey
  T. Barnes

  
	
   

  	
   

  	
   

  	
  Name:
  Jeffrey T. Barnes

  
	
   

  	
   

  	
   

  	
  Title:
  General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  OXFORD
  BIOSCIENCE PARTNERS IV L.P.

  
	
   

  	
   

  	
  By: OBP
  Management IV L.P., its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Jeffrey
  T. Barnes

  
	
   

  	
   

  	
   

  	
  Name:
  Jeffrey T. Barnes

  
	
   

  	
   

  	
   

  	
  Title:
  General Partner

  

 

 

	
   

  	
  GIZA
  EXECUTIVE VENTURE FUND III L.P.

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Avi
  Molcho

  	
   

  
	
   

  	
  Name: Avi
  Molcho

  
	
   

  	
  Title:
  Managing Director

  
	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ Zvi
  Schecter

  	
   

  
	
   

  	
  Name: Zvi
  Schechter

  
	
   

  	
  Title:
  Managing Director

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  GIZA
  ALPINVEST VENTURE FUND III L.P.

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Avi
  Molcho

  	
   

  
	
   

  	
  Name: Avi
  Molcho

  
	
   

  	
  Title:
  Managing Director

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Zvi
  Schecter

  	
   

  
	
   

  	
  Name: Zvi
  Schechter

  
	
   

  	
  Title:
  Managing Director

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  GIZA GE
  VENTURE FUND III L.P.

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Avi
  Molcho

  	
   

  
	
   

  	
  Name: Avi
  Molcho

  
	
   

  	
  Title:
  Managing Director

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Zvi
  Schecter

  	
   

  
	
   

  	
  Name: Zvi
  Schechter

  
	
   

  	
  Title:
  Managing Director

  
						

 

 

	
   

  	
  GIZA GMULOT
  VENTURE FUND III L.P.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Avi
  Molcho

  	
   

  
	
   

  	
  Name: Avi
  Molcho

  
	
   

  	
  Title:
  Managing Director

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Zvi
  Schecter

  	
   

  
	
   

  	
  Name: Zvi
  Schechter

  
	
   

  	
  Title:
  Managing Director

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  GIZA VENTURE
  FUND III L.P.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Avi
  Molcho

  	
   

  
	
   

  	
  Name: Avi
  Molcho

  
	
   

  	
  Title:
  Managing Director

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Zvi
  Schecter

  	
   

  
	
   

  	
  Name: Zvi
  Schechter

  
	
   

  	
  Title:
  Managing Director

  
					

 

 

	
   

  	
  /s/ Donald S. Baim

  	
   

  
	
   

  	
  Dr. Donald
  S. Baim

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Daniel Burkhoff

  	
   

  
	
   

  	
  Dr. Daniel
  Burkhoff

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Peter J. Fitzgerald

  	
   

  
	
   

  	
  Dr. Peter
  J. Fitzgerald

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Richard Geoffrion

  	
   

  
	
   

  	
  Richard
  Geoffrion

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Martin B. Leon

  	
   

  
	
   

  	
  Dr. Martin
  B. Leon

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Mark Maguire

  	
   

  
	
   

  	
  Mark Maguire

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Arthur Pergament

  	
   

  
	
   

  	
  Arthur
  Pergament

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Paul Spence

  	
   

  
	
   

  	
  Dr. Paul
  Spence

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Paul S. Teirstein

  	
   

  
	
   

  	
  Dr. Paul
  S. Teirstein

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Eberhard Grube

  	
   

  
	
   

  	
  Dr. Eberhard
  Grube

  	
   

  

 

 

	
   

  	
  ABN AMRO
  PARTICIPATIES B.V.

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ M. A.
  van Osis

  	
   

  
	
   

  	
  Name: M. A.
  van Osis

  
	
   

  	
  Director

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name: LPA
  Bergstein

  	
   

  
	
   

  	
  Director

  

 

 

	
   

  	
  MEDICA II
  INVESTMENTS (INTERNATIONAL) L.P.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Yuval Binur

  	
   

  
	
   

  	
  Name: Yuval
  Binur

  
	
   

  	
  Title: GP

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  
	
   

  	
  Title:

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  MEDICA II
  INVESTMENTS (P.F) (ISRAEL) L.P.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Yuval Binur

  	
   

  
	
   

  	
  Name: Yuval
  Binur

  
	
   

  	
  Title: GP

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  
	
   

  	
  Title:

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  MEDICA II
  INVESTMENTS (ISRAEL) L.P.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Yuval Binur

  	
   

  
	
   

  	
  Name: Yuval
  Binur

  
	
   

  	
  Title: GP

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  
	
   

  	
  Title:

  
						

 

 

	
   

  	
   

  	
   

  
	
   

  	
  /s/ Volker Trenz    /s/ Rolf
  Käse

  	
   

  
	
   

  	
  (Dr. Paolo Cremascoli

  	
   

  
	
   

  	
  represented by

  	
   

  
	
   

  	
  Volker
  Trenz and Dr. Rolf Käse

  	
   

  
	
   

  	
  on the basis of their power of attorney)

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Volker Trenz    /s/ Rolf
  Käse

  	
   

  
	
   

  	
  (Guido Derjung

  	
   

  
	
   

  	
  represented by

  	
   

  
	
   

  	
  Volker
  Trenz and Dr. Rolf Käse

  	
   

  
	
   

  	
  on the basis of their power of attorney)

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Rolf Käse

  	
   

  
	
   

  	
  (Dr. Rolf Käse)

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Volker Trenz    /s/ Rolf
  Käse

  	
   

  
	
   

  	
  (Dirk Michels

  	
   

  
	
   

  	
  represented by

  	
   

  
	
   

  	
  Volker
  Trenz and Dr. Rolf Käse

  	
   

  
	
   

  	
  on the basis of their power of attorney)

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Volker Trenz    /s/ Rolf
  Käse

  	
   

  
	
   

  	
  (Christoph Nix

  	
   

  
	
   

  	
  represented by

  	
   

  
	
   

  	
  Volker
  Trenz and Dr. Rolf Käse

  	
   

  
	
   

  	
  on the basis of their power of attorney)

  	
   

  

 

 

	
   

  	
   

  	
   

  
	
   

  	
  /s/ Volker Trenz    /s/ Rolf
  Käse

  	
   

  
	
   

  	
  (Prof. Dr. Günter Rau

  	
   

  
	
   

  	
  represented by

  	
   

  
	
   

  	
  Volker
  Trenz and Dr. Rolf Käse

  	
   

  
	
   

  	
  on the basis of their power of attorney)

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Volker Trenz    /s/ Rolf
  Käse

  	
   

  
	
   

  	
  (Community of Heirs After

  	
   

  
	
   

  	
  Prof. Dr. Helmut Reul

  	
   

  
	
   

  	
  represented by

  	
   

  
	
   

  	
  Volker
  Trenz and Dr. Rolf Käse

  	
   

  
	
   

  	
  on the basis of their power of attorney)

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Volker Trenz    /s/ Rolf
  Käse

  	
   

  
	
   

  	
  (Sebastian Schwandtner

  	
   

  
	
   

  	
  represented by

  	
   

  
	
   

  	
  Volker
  Trenz and Dr. Rolf Käse

  	
   

  
	
   

  	
  on the basis of their power of attorney)

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Volker Trenz    /s/ Rolf
  Käse

  	
   

  
	
   

  	
  (Dr. Thorsten Sieß

  	
   

  
	
   

  	
  represented by

  	
   

  
	
   

  	
  Volker
  Trenz and Dr. Rolf Käse

  	
   

  
	
   

  	
  on the basis of their power of attorney)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]